Author Index
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
THE PHILIPPINES, 1942-1944 James Kelly Morningstar, Doctor of History
ABSTRACT Title of Dissertation: WAR AND RESISTANCE: THE PHILIPPINES, 1942-1944 James Kelly Morningstar, Doctor of History, 2018 Dissertation directed by: Professor Jon T. Sumida, History Department What happened in the Philippine Islands between the surrender of Allied forces in May 1942 and MacArthur’s return in October 1944? Existing historiography is fragmentary and incomplete. Memoirs suffer from limited points of view and personal biases. No academic study has examined the Filipino resistance with a critical and interdisciplinary approach. No comprehensive narrative has yet captured the fighting by 260,000 guerrillas in 277 units across the archipelago. This dissertation begins with the political, economic, social and cultural history of Philippine guerrilla warfare. The diverse Islands connected only through kinship networks. The Americans reluctantly held the Islands against rising Japanese imperial interests and Filipino desires for independence and social justice. World War II revealed the inadequacy of MacArthur’s plans to defend the Islands. The General tepidly prepared for guerrilla operations while Filipinos spontaneously rose in armed resistance. After his departure, the chaotic mix of guerrilla groups were left on their own to battle the Japanese and each other. While guerrilla leaders vied for local power, several obtained radios to contact MacArthur and his headquarters sent submarine-delivered agents with supplies and radios that tie these groups into a united framework. MacArthur’s promise to return kept the resistance alive and dependent on the United States. The repercussions for social revolution would be fatal but the Filipinos’ shared sacrifice revitalized national consciousness and created a sense of deserved nationhood. The guerrillas played a key role in enabling MacArthur’s return. -
Correlation of Cytokine Level with the Severity of Severe Fever With
Liu et al. Virology Journal (2017) 14:6 DOI 10.1186/s12985-016-0677-1 RESEARCH Open Access Correlation of cytokine level with the severity of severe fever with thrombocytopenia syndrome Miao-Miao Liu1, Xiao-Ying Lei1, Hao Yu2, Jian-zhi Zhang3 and Xue-jie Yu1,4* Abstract Background: Severe fever with thrombocytopenia syndrome (SFTS) was an emerging hemorrhagic fever that was caused by a tick-borne bunyavirus, SFTSV. Although SFTSV nonstructural protein can inhibit type I interferon (IFN-I) production Ex Vivo and IFN-I played key role in resistance SFTSV infection in animal model, the role of IFN-I in patients is not investigated. Methods: We have assayed the concentration of IFN-α, a subtype of IFN-I as well as other cytokines in the sera of SFTS patients and the healthy population with CBA (Cytometric bead array) assay. Results: The results showed that IFN-α, tumor necrosis factor (TNF-α), granulocyte colony-stimulating factor (G-CSF), interferon-γ (IFN-γ), macrophage inflammatory protein (MIP-1α), interleukin-6 (IL-6), IL-10, interferon-inducible protein (IP-10), monocyte chemoattractant protein (MCP-1) were significantly higher in SFTS patients than in healthy persons (p < 0.05); the concentrations of IFN-α, IFN-γ, G-CSF, MIP-1α, IL-6, and IP-10 were significant higher in severe SFTS patients than in mild SFTS patients (p < 0.05). Conclusion: The concentration of IFN-α as well as other cytokines (IFN-γ, G-CSF, MIP-1α, IL-6, and IP-10) is correlated with the severity of SFTS, suggesting that type I interferon may not be significant in resistance SFTSV infection in humans and it may play an import role in cytokine storm. -
KAPAMPANGAN Aba Abak Abaka Abakan Abala Abante (From The
KAPAMPANGAN ENGLISH PILIPINO akasya acacia (tree) akasya akayagnan simultaneously makasabay pantuhog aba oh! aba akbak spit putok abak morning umaga akbung explosion makita abaka abaca plant abaka akit see aklas abakan breakfast agahan aklas go on strike aklat, libro abala bother abala aklat book abante (from the move forward abante akling reverberation, echo Spanish) ambush abang aklis sorrow tangis abat lie in wait for abangan aklung fold the legs in abatan keep company samahan akmul swallow lunok abayan buddy, friend abay, katoto akmulan throat lalamunan abe milled rice bigas aksaya extravagant aksaya abias emergency abirya aksidenti accident aksidente abirya advise, warning paalala aku me ako abisu pull (verb) hila aku take upon oneself akuin abit response, answer sagot aku (ngaku) "I said" ikako ablás take revenge on paghigantihan akua get makuha ablasanan proceeds of a sale pinagbilhan akut take to, bring over dalahin abli temptation udyok abluk food left over from party adi to pray (with the prefix mang-) manalangin sobra admirul (armirul) starch for clothes armirol abo pay back, refund abono abonu fertilizer adobi adobe block adobe pataba adobu a kind of Filipino dish adobo abonu side pillow abrasador abrasadul April (month) adta sap of tree or plant dagta Abril adua two dalawa Abril fullness, satisfaction kabusugan absi sweet potato rot aduan ask for hingin absik ash aduang hand over iabot abo abu avocado (fruit) aduang-pulu twenty dalawampu abukado abukadu lawyer, attorney aduas fish with a fishing pole bingwit abogado abugadu -
(12) Patent Application Publication (10) Pub. No.: US 2016/0367695A1 Wilson Et Al
US 20160367695A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0367695A1 Wilson et al. (43) Pub. Date: Dec. 22, 2016 (54) POLYPEPTIDE CONSTRUCTS AND USES (30) Foreign Application Priority Data THEREOF Oct. 28, 2011 (AU) ................................ 2011 9045O2 (71) Applicant: Teva Pharmaceuticals Australia Pty Ltd, Macquarie Park (AU) Publication Classification (72) Inventors: David S. Wilson, Freemont, CA (US); Sarah L. Pogue, Freemont, CA (US); (51) Int. Cl. Glen E. Mikesell, Pacifica, CA (US); A6II 47/48 (2006.01) Tetsuya Taura, Palo Alto, CA (US); C07K 6/28 (2006.01) Wouter Korver, Mountain View, CA (52) U.S. Cl. (US); Anthony G. Doyle, Drummoyne CPC ..... A61K 47/48269 (2013.01); C07K 16/2896 (AU); Adam Clarke, Five Dock (AU); (2013.01); C07K 231 7/565 (2013.01); C07K Matthew Pollard, Dural (AU): 2317/55 (2013.01); C07K 2317/92 (2013.01) Stephen Tran, Strathfield South (AU); Jack Tzu Chiao Lin, Redwood City, (57) ABSTRACT CA (US) (21) Appl. No.: 15/194,926 The present invention provides a polypeptide construct (22) Filed: Jun. 28, 2016 comprising a peptide or polypeptide signaling ligand linked to an antibody or antigen binding portion thereof which Related U.S. Application Data binds to a cell Surface-associated antigen, wherein the ligand (63) Continuation of application No. 14/262,841, filed on comprises at least one amino acid Substitution or deletion Apr. 28, 2014, which is a continuation of application which reduces its potency on cells lacking expression of said No. PCT/AU2012/001323, filed on Oct. 29, 2012. antigen. Patent Application Publication Dec. -
WO 2010/142017 Al
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 16 December 2010 (16.12.2010) WO 2010/142017 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 48/00 (2006.01) A61P 37/04 (2006.01) kind of national protection available): AE, AG, AL, AM, A61P 31/00 (2006.01) A61K 38/21 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) Number: International Application DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/CA20 10/000844 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 8 June 2010 (08.06.2010) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/185,261 9 June 2009 (09.06.2009) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, (71) Applicant (for all designated States except US): DE- ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, FYRUS, INC . -
( 12 ) Patent Application Publication ( 10 ) Pub . No .: US 2020/0331966 A1 STOVER Et Al
US 20200331966A1 IN ( 19 ) United States ( 12 ) Patent Application Publication ( 10 ) Pub . No .: US 2020/0331966 A1 STOVER et al . ( 43 ) Pub . Date : Oct. 22 , 2020 ( 54 ) FUSION PROTEIN COMPOSITION ( S ) Related U.S. Application Data COMPRISING MASKED TYPE I INTERFERONS ( IFNA AND IFNB ) FOR USE ( 60 ) Provisional application No. 62 / 920,140 , filed on Apr. IN THE TREATMENT OF CANCER AND 15 , 2019 . METHODS THEREOF Publication Classification ( 71 ) Applicant: Qwixel Therapeutics, Los Angeles, CA ( 51 ) Int. Ci . ( US ) CO7K 7/08 ( 2006.01 ) A61K 47/65 ( 2006.01 ) ( 72 ) Inventors : David STOVER , Encino, CA (US ) ; A61P 35/00 ( 2006.01 ) Sherie MORRISON , Los Angeles, CA ( 52 ) U.S. CI . ( US ) ; Alex VASUTHASAWAT , Los CPC CO7K 7/08 ( 2013.01 ) ; A61K 38/00 Angeles , CA ( US ) ; Kham TRINH , ( 2013.01 ) ; A61P 35/00 ( 2018.01 ) ; A61K 47/65 Porter Ranch , CA ( US ) ; George ( 2017.08 ) AYOUB , Los Angeles, CA ( US ) ( 57 ) ABSTRACT Fusion Protein compositions comprising masked IFNs and ( 73 ) Assignee : Qwixel Therapeutics, Los Angeles, CA methods of making masked IFNs are disclosed herein . ( US ) Consequently, the masked IFNs can be fused to a Mab or binding fragment thereof and be administered to patients as ( 21 ) Appl. No .: 16 /849,889 a therapeutic modality and provide a method of treating cancer, immunological disorders and other disease . ( 22 ) Filed : Apr. 15 , 2020 Specification includes a Sequence Listing . Matripase ST 14 Cleaves an IFN Mask from the Heavy Chain of an anti CD138 Fusion Ab . 1 2 3 1. ant - CD138 / Na 2. anti - C0138 IFNa mask 3. anti - C0138 FNa mask w / MST14 Patent Application Publication Oct. -
United States Patent (10) Patent No.: US 9,464,124 B2 Bancel Et Al
USOO9464124B2 (12) United States Patent (10) Patent No.: US 9,464,124 B2 Bancel et al. (45) Date of Patent: Oct. 11, 2016 (54) ENGINEERED NUCLEIC ACIDS AND 4,500,707 A 2f1985 Caruthers et al. METHODS OF USE THEREOF 4,579,849 A 4, 1986 MacCoSS et al. 4,588,585 A 5/1986 Mark et al. 4,668,777 A 5, 1987 Caruthers et al. (71) Applicant: Moderna Therapeutics, Inc., 4,737.462 A 4, 1988 Mark et al. Cambridge, MA (US) 4,816,567 A 3/1989 Cabilly et al. 4,879, 111 A 11/1989 Chong (72) Inventors: Stephane Bancel, Cambridge, MA 4,957,735 A 9/1990 Huang (US); Jason P. Schrum, Philadelphia, 4.959,314 A 9, 1990 Mark et al. 4,973,679 A 11/1990 Caruthers et al. PA (US); Alexander Aristarkhov, 5.012.818 A 5/1991 Joishy Chestnut Hill, MA (US) 5,017,691 A 5/1991 Lee et al. 5,021,335 A 6, 1991 Tecott et al. (73) Assignee: Moderna Therapeutics, Inc., 5,036,006 A 7, 1991 Sanford et al. Cambridge, MA (US) 9. A 228 at al. J. J. W. OS a 5,130,238 A 7, 1992 Malek et al. (*) Notice: Subject to any disclaimer, the term of this 5,132,418 A 7, 1992 °N, al. patent is extended or adjusted under 35 5,153,319 A 10, 1992 Caruthers et al. U.S.C. 154(b) by 0 days. 5,168,038 A 12/1992 Tecott et al. 5,169,766 A 12/1992 Schuster et al. -
W O 2014/151535 a L 2 5 September 2014 (25.09.2014) P O P C T
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date W O 2014/151535 A l 2 5 September 2014 (25.09.2014) P O P C T (51) International Patent Classification: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, C07K 14/705 (2006.01) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (21) International Application Number: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, PCT/US20 14/025940 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (22) International Filing Date: TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, 13 March 2014 (13.03.2014) ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (30) Priority Data: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 61/791,537 15 March 2013 (15.03.2013) TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 61/787,753 15 March 2013 (15.03.2013) EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (71) Applicant: BAYER HEALTHCARE LLC [US/US]; 555 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, White Plains Rd., Tarrytown, NY 10591 (US). -
Printed from Woolley & Wallis
Printed from Woolley & Wallis Sale: Day 1 - Tribal Art the Americas, Indonesia & Oceania Wednesday 18th September 2019 10:00AM 579 lots in this sale All lots are subject to the Buyer’s Premium at 25% + VAT. Lot Description Estimate Hammer 1001 An Inca effigy container conopa £150 - £250 £60 1002 A Chimu weaving shuttle £150 - £250 £150 1003 Two Veracruz head fragments £180 - £220 £140 1004 A Costa Rica metate grinding stone £400 - £600 1005 A Chontal style mask £200 - £300 £50 1006 A pair of Peruvian figures £150 - £200 1007 Two Peru miniature masks £200 - £300 £180 1008 A Nayarit figural vessel £200 - £300 1009 Three Peruvian vessels £150 - £250 1010 A pair of Chancay figures £400 - £600 1011 An Inca style two handled vessel £150 - £250 £160 1012 WITHDRAWN 0 1013 Four Peruvian dolls £100 - £200 £90 1014 A Chancay textile fragment £100 - £200 1015 Twelve Pre-Columbian textile fragments £200 - £300 £170 1016 Eleven Pre-Columbian textile fragments £200 - £300 £160 1017 Eight Pre-Columbian textile fragments £250 - £350 1018 Ten Pre-Columbian textile fragments £300 - £400 1019 Ten Pre-Columbian textile fragments £200 - £300 1020 Eight Pre-Columbian textile fragments £200 - £300 1021 An Amazon club £200 - £300 £200 1022 A Guyana club £500 - £700 £700 1023 An Amazon club £100 - £150 £60 Lot Description Estimate Hammer 1024 λA Tierra del Fuego harpoon head £200 - £300 £110 1025 A Guyana small club £200 - £300 £420 1026 A Hopewell type pipe bowl £400 - £600 £400 1027 A Zuni bear fetish £100 - £150 £480 1028 A Sami knife and sheath £40 - £60 £90 -
Severe Sepsis Epidemiology and Sex-Related Differences in Inflammatory Markers
UMEÅ UNIVERSITY MEDICAL DISSERTATIONS NEW SERIES NO. 1680 ISSN 0346-6612 ISBN: 978-91-7601-149-2 From the Department of Surgical and Perioperative Sciences Anesthesiology and Intensive Care Medicine Umeå University, Sweden Severe sepsis Epidemiology and sex-related differences in inflammatory markers. Sofie Jacobson Fakultetsopponent: Professor Else Tönnesen Dept. of Clinical Medicine - Anaesthesiology Århus, Danmark Umeå 2014 Cover illustration: "First line of defence" Anders Jacobsson Copyright © 2014 Sofie Jacobson ISBN: 978-91-7601-149-2 NEW SERIES NO. 1680 ISSN 0346-6612 Layout and printed by: Print & Media Umeå, Sweden 2014 To my family A goal is a dream with a deadline. ~ Napolean Hill Contents CONTENTS ABSTRACT......................................................................................................................... iv Svensk sammanfattning .........................................................................................................v Abbreviations..................................................................................................................... viii ORIGINAL PAPERS............................................................................................................x PROLOGUE ........................................................................................................................xi INTRODUCTION..................................................................................................................1 Epidemiology ....................................................................................................................2 -
KAPAMPANGAN Aba Abak Abaka Abakan Abala Abante (From The
ENGLISH KAPAMPANGAN PILIPINO oh! aba aba morning abak umaga abaca plant abaka abaka breakfast abakan agahan bother abala abala move forward abante (from the Spanish) abante ambush abat abang lie in wait for abatan abangan keep company abayan samahan buddy, friend abe abay, katoto milled rice abias bigas emergency abirya abirya advise, warning abisu paalala pull (verb) abit hila response, answer ablás sagot take revenge on ablasanan paghigantihan proceeds of a sale abli pinagbilhan temptation abluk udyok food left over from party abo sobra pay back, refund abonu abono fertilizer abonu pataba side pillow abrasadul abrasador April (month) Abril Abril fullness, satisfaction absi kabusugan sweet potato rot absik ash abu abo avocado (fruit) abukadu abukado lawyer, attorney abugadu abogado crease, rib of a leaf abulud liston needing to pay back, suffer a abunadu abunado loss abusadu abusado abusive abusu abuso abuse abut abot reach abubut abubot knicknacks abwang drive back abyas milled rice bigas akasya acacia (tree) akasya akayagnan simultaneously makasabay akbak spit pantuhog akbung explosion putok akit see makita aklas go on strike aklas aklat book aklat, libro akling reverberation, echo aklis sorrow tangis aklung fold the legs in akmul swallow lunok akmulan throat lalamunan aksaya extravagant aksaya aksidenti accident aksidente aku me ako aku take upon oneself akuin aku (ngaku) "I said" ikako akua get makuha akut take to, bring over dalahin adi to pray (with the prefix mang-) manalangin admirul (armirul) starch for clothes armirol adobi -
Hepatitis C Virus and Interferon Type
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector REVIEW 10.1111/1469-0691.12797 Hepatitis C virus and interferon type III (interferon-k3/interleukin-28B and interferon-k4): genetic basis of susceptibility to infection and response to antiviral treatment E. Riva1, C. Scagnolari2, O. Turriziani2 and G. Antonelli2 1) Department of Integrated Research, Virology Section, University Campus Bio-Medico of Rome and 2) Department of Molecular Medicine, Virology Section, Sapienza University of Rome, Rome, Italy Abstract There has been a significant increase in our understanding of the host genetic determinants of susceptibility to viral infections in recent years. Recently, two single-nucleotide polymorphisms (SNPs), rs12979860 T/C and rs8099917 T/G, upstream of the interleukin (IL)-28B/interferon (IFN)-k3 gene have been clearly associated with spontaneous and treatment-induced viral clearance in hepatitis C virus (HCV) infection. Because of their power in predicting the response to IFN/ribavirin therapy, the above SNPs have been used as a diagnostic tool, even though their relevance in the management of HCV infection will be blunt in the era of IFN-free regimens. The recent discovery of a new genetic variant, ss469415590 TT/DG, upstream of the IL-28B gene, which generates the novel IFN-k4 protein, has opened up a new and alternative scenario to understand the functional architecture of type III IFN genomic regions and to improve our knowledge of the pathogenetic mechanism of HCV infection. A role of ss469415590 in predicting responsiveness to antiviral therapy has also been observed in HCV-infected patients receiving direct antiviral agents.